Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6244523 | 0.81 | SYK (0.51) | CTSSCTSLCTSBSYKAKT1 | |
| SCHEMBL22833183 | 0.79 | CTSL (0.54) | CTSSCTSLCTSBSYKAKT1 | |
| SCHEMBL5059307 | 0.78 | CTSL (0.47) | CTSSCTSLCTSBSYKAKT1 | |
| SCHEMBL8630273 | 0.78 | HDAC3 (0.52) | CTSSCTSLCTSBAKT1HDAC3 | |
| SCHEMBL6371020 | 0.77 | MEN1 (0.47) | CTSSCTSLCTSBSYKCTSK | |
| SCHEMBL8647499 | 0.76 | HDAC3 (0.53) | CTSSCTSLCTSBAKT1HDAC3 | |
| SCHEMBL8021840 | 0.75 | HDAC3 (0.55) | CTSSCTSLCTSBAKT1HDAC3 | |
| SCHEMBL17571450 | 0.75 | SYK (0.56) | CTSSCTSLCTSBSYKAKT1 | |
| SCHEMBL22678944 | 0.75 | SYK (0.56) | CTSSCTSLCTSBSYKAKT1 | |
| SCHEMBL30802196 | 0.75 | SYK (0.50) | CTSSCTSLCTSBSYKAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005118613-A2 | ANTIBACTERIAL AMIDE MACROCYCLES | AICURIS GMBH & CO.KG (DE) | 2005-12-15 | — | — | WO | disclosed |
| US-20050256037-A1 | Antibacterial amide macrocyles | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256037-A1 | Antibacterial amide macrocyles | AADAC, PAM, NOD2 | CTSS 99/4885CTSL 71/4885CTSB 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.